Xeris legal chief sells 16,666 shares under plan

Beth Hecht’s sale leaves her with about 1.13 million XERS shares after the Sept. 1 open-market transaction.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) insider Beth Hecht, Chief Legal Officer and Corporate Secretary, reported selling 16,666 shares of common stock on 2026-09-01 in an open-market transaction under a Rule 10b5-1 trading plan adopted on 2025-08-08. The weighted average sale price was $8.4864 per share, from multiple trades between $8.390 and $8.600. Following this sale, Hecht directly holds 1,127,796 shares of XERS common stock.

Insider Trade Summary 10b5-1

Net Seller: 16,666 shares

Net Sell 1 txn

Insider Hecht Beth

Role See Remarks

Sold 16,666 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	16,666	$8.4864	$141K

Holdings After Transaction: Common Stock — 1,127,796 shares (Direct)

Footnotes (2)

1. F1. The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 16,666 shares Weighted average sale price: $8.4864 per share Price range of sales: $8.390 to $8.600 per share +2 more

5 metrics

Shares sold 16,666 shares Common Stock sale on 2026-09-01

Weighted average sale price $8.4864 per share Average price for 16,666 shares sold

Price range of sales $8.390 to $8.600 per share Range of prices for multiple trades in the transaction

Shares owned after transaction 1,127,796 shares Direct holdings of Beth Hecht following the sale

Rule 10b5-1 plan adoption date August 8, 2025 Date Hecht adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did XERS disclose for Beth Hecht?

Beth Hecht reported a sale of 16,666 XERS common shares on 2026-09-01 in an open-market transaction, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, she directly owns 1,127,796 XERS shares.

At what price were the 16,666 XERS shares sold by Beth Hecht?

The reported price is a weighted average of $8.4864 per share. The 16,666 shares were sold in multiple trades at prices ranging from $8.390 to $8.600 per share, inclusive.

How many XERS shares does Beth Hecht own after the reported sale?

Following the reported transaction, Beth Hecht directly holds 1,127,796 shares of Xeris Biopharma Holdings, Inc. common stock, as disclosed in the Form 4 filing.

Was the XERS insider sale by Beth Hecht under a Rule 10b5-1 plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Beth Hecht on August 8, 2025, as stated in the footnotes to the transaction.

What role does Beth Hecht have at Xeris Biopharma Holdings, Inc. (XERS)?

Beth Hecht is identified as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., according to the remarks section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 06:21 PM EDT Accepted by SEC EDGAR 09/01/2026 - 06:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		16,666	D	$8.4864(2)	1,127,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)